In the deal expected to close in the third quarter, Eli Lilly will buy Dice for $48 per share in cash, according to a June 20 joint news release from the companies. Dice uses proprietary technology to develop oral therapeutic drugs to treat autoimmune diseases. The company has inhibitors in clinical development, and its lead drug is for psoriasis and is in a midstage trial, according to CNBC.
“In combination with its novel technology and expertise in drug discovery, Dice’s talented workforce and passion for innovation will enhance our efforts to make life better for people living with devastating autoimmune diseases,” Patrik Jonsson, executive vice president at Eli Lilly, said in a the release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
